We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?
- Authors
Friedlaender, Alex; Banna, Giuseppe; Malapelle, Umberto; Pisapia, Pasquale; Addeo, Alfredo
- Abstract
Lung cancer is the leading cause of cancer-related mortality and will affect ~6% of the population. It is divided into two broad categories, small cell lung cancer and non-small cell lung cancer (NSCLC), the latter representing 85% of all lung cancers. It mainly comprises adenocarcinoma (65%) and squamous cell carcinoma (30%) histologies. In recent years, there have been two major therapeutic advances in NSCLC. The first, immunotherapy, has greatly improved the prognosis of adenocarcinomas and squamous cell carcinomas. The second, the treatment of targetable driver mutations, has so far only benefited adenocarcinomas. Squamous cell carcinoma carries a high rate of mutations and is found mostly among smokers. This raises two important problems: identifying driver mutations and finding those of clinical relevance. Large-scale genomic analyses such as The Cancer Genome Atlas have allowed for the identification of frequent gene alterations, although their role and potential for targeted therapy remain unknown. The emergence of next generation sequencing has changed the landscape of precision medicine, in particular in lung cancer. In this review, we discuss the landscape of genetic alterations found in squamous cell lung cancer, the results of current targeted therapy trials, the difficulties in identifying and treating these alterations and how to integrate modern tools in clinical practice.
- Subjects
SQUAMOUS cell carcinoma; SMALL cell lung cancer; GENETIC mutation; INDIVIDUALIZED medicine; IMMUNOTHERAPY
- Publication
Frontiers in Oncology, 2019, pN.PAG
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2019.00166